An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma

• Published in: The Journal of clinical investigation Vol. 132; no. 16; pp. 1 - 17
• Main Authors: Tian, Meijie, Cheuk, Adam T, Wei, Jun S, Abdelmaksoud, Abdalla, Chou, Hsien-Chao, Milewski, David, Kelly, Michael C, Song, Young K, Dower, Christopher M, Li, Nan, Qin, Haiying, Kim, Yong Yean, Wu, Jerry T, Wen, Xinyu, Benzaoui, Mehdi, Masih, Katherine E, Wu, Xiaolin, Zhang, Zhongmei, Badr, Sherif, Taylor, Naomi, St Croix, Brad, Ho, Mitchell, Khan, Javed
• Format: Journal Article
• Language: English
• Published: Ann Arbor American Society for Clinical Investigation 01.08.2022
• Subjects: Antigen (tumor-associated); Antigens; Biomedical research; Cell adhesion & migration; Children; Chimeric antigen receptors; Clinical trials; Cytotoxicity; Epitopes; Heparan sulfate proteoglycans; Immunotherapy; Kinases; Lymphocytes; Lymphocytes T; Lymphoma; Medical prognosis; Metastasis; Neuroblastoma; Pediatrics; Protein expression; Proteins; Solid tumors; Transcriptomes; Tumor cells; Tumors

Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated antigens (TAAs), limited T cell persistence, and T cell exhaustion. Here, we aimed to identify optimal CARs against...